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Activin, inhibin, and follistatin are protein hormones, all of
which were originally isolated from gonads as regulatory
factors of pituitary follicle-stimulating hormone (FSH)
secretion. Inhibin and activin are structurally related glycopro-
teins, consisting of two subunits linked by disulphide bonds
(Robertson et al, 1985; Vale et al, 1986; Ying 1988; Hillier,
1991). Inhibin is composed of an a subunit and one of the two
b subunits (ba or bb), whereas activin is formed from a combi-
nation of two of the same or different b subunits. The function
of activin is thought to be mediated through binding to a
receptor complex containing at least two proteins, referred to
as type I and type II ActRs (Hino et al, 1989; Kondo et al,
1989). Cloning of cDNAs encoding the type I and II activin
receptors (ActRs) in various species has shown that there are
multiple isoforms for each type of receptor. In the human, two
isoforms of the type I receptor, ActR Ia (Attisano et al, 1993)
and ActR Ib (ten Dijke et al, 1994; Xu et al, 1994), have been
identified.
Both mRNAs of inhibin subunits and ActRs have been reported
to be expressed in some ovarian carcinoma cell lines, and activin
has been reported to have a proliferative effect in these cells (Di
Simone et al, 1996). In recent years, techniques have been devel-
oped to culture normal human ovarian epithelial cells (Kruk et al,
1990) and malignant cells from ovarian cancer patients (Hamilton
et al, 1983). These studies have shown that ovarian surface epithe-
lial cells retain sensitivity to a number of growth factors and may
require their presence for proliferation. The follicular fluid
released from the follicle at the time of ovulation flows over the
surface of the ovary and growth factors present in the follicular
fluid, including activin, may provide stimuli for the proliferation
of surface epithelial cells during the healing process that follows
ovulation. Thus, it is interesting to know whether OSE cells are
capable of responding to activin through specific receptors.
Transforming growth factor (TGF)-b family members elicit
their multifunctional effects through heteromeric complexes of
type I and type II serine/threonine kinase receptors (Mathews,
1994; Massague, 1996; Derynck and Feng, 1997). Upon activin
binding to a type II receptor with constitutively active kinase, the
type I receptor is recruited and phosphorylated and activated by
type II receptor kinase (Attisano and Wrana, 1996; Willis et al,
1996). Members of the Smad-and Mad-related (Smad) protein
family are known to play pivotal roles in intracellular TGF-b
family signalling (Heldin et al, 1997). Smads located in the
cytoplasm are directly phosphorylated by membrane serine/-
threonine kinase receptors that bind TGF-b or the related factors
activin and bone-morphogenic protein (BMPs). The phosphory-
lated Smads then move into the nucleus as complexes that bind
specific DNA sequences in target promoters, thus activating
transcription.
Smad 2 and Smad 4 have been suggested as possible
downstream signals of activin receptors. To determine if
mRNAs for Smad 2 and Smad 4 are expressed in ovarian cancer
cell lines, Northern blot hybridization was performed on the
total RNA isolated from these cells. In this study, the expression
of the inhibin subunits and ActRs was determined in normal and
malignant ovarian cells, and the levels of Smad 2 and Smad 4
mRNA were examined in OVACAR 3 cells stimulated with
activin A.
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Summary In this study, we have investigated the expression of inhibin subunits and activin receptors (ActRs) in normal and malignant ovarian
cells. Each product of the inhibin subunits (a, ba, bb) and activin receptors (ActRs) amplified by reverse transcription polymerase chain
reaction were detected as a single band in human granulosa cells, surface epithelial cells (OSE), and the ovarian cancer cell lines OVCAR 3
and SKOV 3. Western blot analysis was performed using polyclonal antibodies against ActR IIa or IIb peptides based on 13 COOH-terminal
amino acids; cultured human granulosa cells were used as a positive control. Using ActR IIa antibody, one major band corresponding to
approximately 80 kDa and one minor band corresponding to 105 kDa were observed in the samples. One single band at approximately
60 kDa was detected in OVCAR 3 and a 50 kDa band was detected with ActR IIb antibody in cultured granulosa cell, OSE and SKOV 3.
Although no detectable change was induced in Smad 4 mRNA in OVCAR 3, Smad 2 mRNA levels were increased during 48 h treatment with
activin A (50 ng ml–1). These data provide a better understanding as the first step in the mechanism of action of the activin in the epithelial
ovarian carcinoma. © 2000 Cancer Research Campaign
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Cell culture and treatment
OVCAR 3 and SKOV 3, which are epithelial ovarian cancer cell
lines derived from adenocarcinomas, were obtained from the
American Tissue Culture Collection (ATCC, Rockville, MD,
USA). Cells were cultured in medium 199 (M199) containing 10%
heat inactivated fetal bovine serum (FBS) (Gibco-BRL), 100 U
penicillin G ml–1 and 100 mg streptomycin ml–1 (Sigma Chemical
Co., St Louis, MO, USA) at 37°C in 5% carbon dioxide 95% air.
Then, 0.5 ´ 106 cells ml–1 were plated in 60 mm culture dishes
(Falcon) and cultured for 48 h. When they were near confluent, the
cells were washed with M199 and medium was changed. Cells
were lysed with lysis buffer (50 mM Tris–HCl pH 8.0, 150 mM
sodium chloride, 0.02% sodium azide, 1% Triton X-100, 1 mg
ml–1 aprotinin, 100 mg ml–1 phenylmethylsulphonyl fluoride) for
Western blot analysis and lysed with 4 M guanidine isothiocyanate
containing 1% b-mercaptoethanol (ME) for reverse transcription
polymerare chain reaction (RT-PCR) analysis. To study the effects
of activin on expression of Smads mRNA, OVCAR 3 cells were
cultured in 60-mm dishes containing 1 ´ 106 cells in 5-ml M 199
with 0.1% BSA and 50 ng ml–1 activin was added to the medium
after 24 h of cell culture. Cells were further incubated and incuba-
tion was stopped at 24 h, 48 h and 72 h, and total RNA was
extracted from the cultured cells.
Ovarian surface epithelium was scraped from the surface of
grossly normal ovaries that were obtained with consent from
patients having surgery for benign gynaecologic diseases. The
cells were cultured as described previously (Kruk et al, 1990) in M
199/MDCB 105/15% FBS with 2 ml ml–1 gentamicin and passaged
with 0.06% trypsin (1:250) and 0.01% ethylenediaminetetraacetic
acid when confluent. The cells’ origin in ovarian surface epithe-
lium was initially confirmed by their characteristic epithelial
morphologic features and keratin expression (Siemens and
Auersperg 1988). The cells when they were almost confluent in
35-mm dishes in passage 1 were lysed with lysis buffer for
Western blot analysis and lysed with 4 M guanidine isothiocyanate
containing 1% b-ME for RT-PCR analysis.
Human granulosa cells were collected and cultured as described
previously (Li et al, 1992). Then, 0.5 ´ 106 cells ml–1 were plated
in 35-mm dishes and cultured for 48 h and the cells were lysed
with lysis buffer for Western blot analysis and lysed with 4 M
guanidine isothiocyanate containing 1% b-ME for RT-PCR
analysis.
RT-PCR and Southern blot procedures
Total RNA was isolated and extracted using the guanidinium
isothiocyanate method (Chomczynski and Sacchi, 1987). The
RNA concentrations were quantified by measuring the absorbance
of samples at 260 nm. Complementary DNA (cDNA) was synthe-
sized from 3 mg total RNA, using a first-strand cDNA synthesis kit
(Pharmacia Ltd, Uppsala, Sweden). Synthesized cDNA (1 ml from
total 15 ml) was used as template for PCR amplification where 28
cycles consisted of denaturing at 96°C for 30 s, annealing at 51°C
(ba, bb subunits), 53°C (a subunit, ActR IIa), 55°C (ActR Ia),
57°C (ActR IIb) for 30 s and extension at 72°C for 1.5 min. At
final cycle, a 15 min, 72°C extension step was added. The oligo-
nucleotide primers used for amplification were derived from
human inhibin a,  ba,  bb, ActR Ia, ActR IIa, ActR IIb cDNA
sequences (Mason et al, 1986, 1989; Tanimoto et al, 1991). The
sequence of each primers are previously described (Fukuda et al,
1998). Following electrophoresis in 1% agarose gels, the PCR
products were visualized with an UV light by staining with 1 mg
ml–1 ethidium bromide solution. The cDNAs were transferred to
nylon membranes (Hybond-N, Amersham) and fixed by UV irra-
diation. Blots were prehybridized for 3 h at 42°C in the presence
of 50% formamide under standard conditions, and hybridized
overnight at 42°C with digoxigenin-labelled cDNA probes. Inserts
from the inhibin Ha4, HbA-4, GbB-5 clones (kindly supplied by
Dr H Meunier) and the ActR Ia, IIa, IIb cDNA were labelled as
digoxigenin with cDNA-labelling kit (Boehringer Mannheim).
Complementary DNA of ActR Ia, IIa and IIb were obtained and
sequenced from the PCR products from the human placenta.
Under the standard protocol for the DIG luminescence detection
kit (Boehringer Mannheim), the blots were exposed at room
temperature to X-ray film for 2 min.
Western blot analysis
A total of 2 ´ 106 OVCAR 3 cells were washed three times with
ice-cold phosphate-buffered saline (PBS), and dissolved in lysis
buffer by incubating for 30 min at 4°C. Following centrifuging for
5 min at 2000 g, the solubilized supernatants were separated by
sodium dodecyl sulphate polyacrylamide gel electrophoresis
(SDS-PAGE) in the presence of 1% b-ME, using 8% gels. Proteins
were transferred to Hybond C membrane (Amersham Corp.).
ActR IIa, IIb were detected with polyclonal antibodies produced in
rabbits by synthetic peptide from the carboxyl-terminal sequences
of ActR IIa and IIb (kindly provided by Dr Vale). Bound anti-
bodies were detected using enhanced chemiluminescent (ECL)
detection kit (Amersham Corp.). The solubilized protein concen-
tration were measured by BioRAD protein assay (BioRAD), each
25 mg protein per lane was separated by SDS-PAGE.
Cloning of Smad 2 and Smad 4 cDNA
Oligonucleotides for PCR were designed to include all possible
sequence encoding cording regions of Smad 2 and Smad 4,
with the addition of Pst and Echo restriction sites for Smad 2.
During PCR for Smad 2, Pst and EcoRI restriction sites were
incorporated at the 5¢ and 3¢ ends of cDNA using primer
5¢-CCACTGCAGGTTCGATACAAGAGGCTGTT-3¢(1–22) and
5¢-CCGGAATTCTGGATAGTAAACAGCCATAGGGACCA-3¢
(1529–1554) respectively (Zhang et al, 1996).
For Smad 4, BamH1 restriction site was incorporated at the 5¢
end of cDNA using primer 5¢-CTAGGATCCCCTTGCAACGT-
TAGCTGTT-3¢ (30–50) and 3¢ end of cDNA 5¢-AAAA-
GATAAAGEAGAAGAAAAGTGA-3¢ (1894–1870) respectively
(Hahn et al, 1996). PCR was performed using cDNA synthesized
from placental total RNA. The generated PCR products were
cloned into Blueskript KS(+) and pGEM vectors. DNA
sequencing were carried out using the dideoxy chain termination
method.
RNA extraction and Northern blot analysis
Total RNA was extracted from the cultured cells by the guanidium
thiocyanate method (Chomczynski and Sacchi, 1987). The final
RNA pellet was dissolved in dimethyl pyrocarbonate-treated
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of samples at 260 nm. For Northern blot analysis, 10 mg of total
RNA were separated by electrophoresis on denaturing agarose gels
and subsequently transferred to a nylon membrane (Biodyne, ICN,
Glen Cove, NY, USA). Northern blots were hybridized at 68°C
with digoxigenin-labelled cRNA probes. In accordance with the
standard protocol for the nucleic acid detection kit used
(Boehringer Mannheim), membranes were then exposed to Kodak
X-omat film (Eastman Kodak, Rochester, NY, USA). Smad 2
cDNA was subcloned into the Bluescript vector and linearized
with  PstI. Smad 4 was subcloned into pGEM vector and linearized
with SphI. Digoxigenin-labelled cRNA probes were produced by
in vitro transcription with T3 for Smad 2 or SP6 for Smad 4 RNA
polymerase and with an RNA labelling kit (Boehringer
Mannheim). Digoxigenin-labelled GAPDH (gluceraldehyde 3-
phosphate dehydrogenase) cRNA probes were obtained by the
same method. The relative abundance of a 4.0 (kb) signal for Smad
2 mRNA in different preparations were quantified with a LKB
2202 UnitroScan Laser Densitometer (LKB Producter AB,
Bromma, Sweden), normalized against levels of GAPDH mRNA
in each sample, and expressed as a percentage of the control value
(100%). The data are presented as the mean ± s.e.m. of measure-
ments from triplicate cultures for one representative experiment.
Statistical analysis
Values were considered significantly different for values of
P < 0.05 as determined by one-way analysis of variance
(ANOVA).
RESULTS
Expression of inhibin subunit mRNAs
Each product of the inhibin subunits (a, ba, bb) amplified by RT-
PCR was detected as a single band in the human granulosa cells,
OSE, OVCAR 3 and SKOV 3 (Figure 1). Each size was found to
correspond to the predicted fragment size. The ba subunit is only
weakly expressed in OSE. The authenticity of the PCR-products
was further confirmed by Southern blotting using the inhibin
subunits cDNA probes.
Expression of ActR mRNAs
ActR Ia, IIa and IIb, all amplified by RT-PCR, were detected as
single bands (Figure 2). Each size was found to correspond to the
predicted fragment size. The ActR Ia is minimal in granulosa cells
and modest in OSE compared to the two ovarian cancer cell lines.
The ActR IIb is expressed very little by all of the samples. The
authenticity of the PCR-products was further confirmed by
Southern blotting using the inhibin subunits cDNA probes, and
ActR IIb alone was shown in Figure 2C.
Western blot analysis of ActR IIa and IIb
Western blot analysis was performed using polyclonal antibodies
against ActR IIa or IIb peptides based on 13 COOH-terminal
amino acids (Figure 3). Cultured human granulosa cells were used
as a positive control. Using ActR IIa antibody, one major band
corresponding to approximately 80 kDa and one minor band corre-
sponding to 105 kDa were observed in all samples except OSE. As
shown in previous experiments (Fukuda et al, 1998), the larger
molecular weight signals might be the result of an activin and
ActR complex. One single band of approximately 60 kDa was
detected in OVCAR 3 and a 50 kDa band was detected in the gran-
ulosa cells, OSE and SKOV 3 with ActR IIb antibody. Although
the reasons for this difference have not been clarified, this effect
might be due to differences in glycosylation or mutation.
Expression of mRNAs for Smad 2 and Smad 4 in
OVCAR 3 and SKOV3
Smad 2 and Smad 4 have been suggested as possible downstream
signals of activin receptors. To determine if mRNAs for Smad 2
and Smad 4 are expressed in ovarian cancer cell lines, Northern
blot hybridization was performed on the total RNA isolated from
these cells. Two transcripts with sizes of 4.5 kb and 2.9 kb, respec-
tively, were observed in these samples when the Smad 2 cDNA
probe was used. Only one transcript size (4.2 kb) for Smad 4 was
detected in both cell lines. To determine the time-course effects
of activin on Smad expression, the cell lines were treated with
50 ng ml–1 activin for various durations. No detectable changes
were observed in Smad 2 and Smad 4 mRNA with activin treat-
ment in SKOV 3 (data not shown). Although no detectable change
was induced in Smad 4 mRNA during 72 h treatment with activin
in OVCAR 3, Smad 2 mRNA levels gradually increased and
significantly higher than that of control at 72 h (Figure 4).
DISCUSSION
Inhibin and activins are members of the TGF-b superfamily of
polypeptides that have been shown to have both growth-promoting
and growth-inhibiting properties (Roberts et al, 1985; Vale et al,
1988; Bernstein et al, 1990; Berchuck et al, 1992; Fynan and
Reiss, 1993). The importance of inhibin and its a-subunit in the
regulation of stromal cell proliferation and tumour development
has been recently demonstrated by using a homologous recombi-
nation to the a-subunit from the mouse genome (Matzuk et al,
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Figure 1 PT-PCR amplification of inhibin subunits (a, b a and b b). Ethidium
bromide stained PCR-product (28 cycles) were separated on 1% agarose
gel. Lanes: 1, human cultured luteal-granulosa cells obtained from IVF-ET
patients; 2, OSE; 3, OVCAR 3; 4, SKOV 31992). The loss of the inhibin a-subunit in these mice results in
stromal tumour development within 6 weeks. Interestingly, the
a-inhibin-deficient mice all had extremely elevated levels of
circulating activin. Thus, the absence of the inhibin a-subunit or
overexpression and secretion of the inhibin/activin b-subunit and
dimeric activin may contribute to the development of gonadal
stromal tumours.
There is a evidence suggesting that epithelial ovarian carci-
nomas express the activin receptors and this would indicate that
activin also influences the growth of ovarian epithelial carcinomas
(Welt et al, 1997). Therefore, if it were possible to clarify the pres-
ence of activin receptors in epithelial cells it might also facilitate
an understanding of the mechanism of tumour development from
ovarian epithelial cells. In this study, OSE cells were shown to
express all of the inhibin subunits and ActR Ia, IIa and IIb mRNA,
using RT-PCR and Southern blot. Furthermore, it was initially
revealed that OSE expressed the ActR IIa and IIb proteins. These
findings support the idea that activin and its receptors may be
effective via an autocrine/paracrine mechanism acting on normal
ovarian functions and on malignant growth in epithelial carci-
noma. Therefore, the results of the present study support the
hypothesis that potent growth factors present in the preovulatory
follicle may be involved in regulating both the proliferation of the
epithelial cells that cover the surface of the ovary and the subse-
quent development of malignant neoplasia. The healing occurring
after each ovulation would require rapid mitotic activity in epithe-
lial cells. Growth factors such as activin, which are present in the
follicular fluid, may provide the stimulus for this proliferation.
These same growth factors may also promote the growth of
neoplastic epithelium.
Although the precise events leading to malignant transformation
and progression of ovarian cancer cells are not known, it is known
that multiple steps are involved. Furthermore, it has been
suggested that the autonomous growth of transformed cells might
be due to a constitutive expression of growth factors and
membrane receptors. In this experiment, we have shown that, in
addition to granulosa cells (Eramaa et al, 1995), cultured OSE
cells, OVCAR 3 and SKOV 3 cells release inhibin subunits and
that these cells possess receptors for activin. Improved under-
standing of the cellular action of receptor serine kinases has been
achieved since the discovery of the newly described Smad family
of proteins. Distinct subclasses of Smad proteins can be positively
or negatively modulated alone or in combination with activin and
TGF-b responses.
Smad 1, Smad 2, Smad 3 and Smad 5 become phosphorylated
by specific, activated type I serine/threonine kinase receptors and
thus these proteins act in a pathway-restricted fashion. Smad 4
forms hetero-oligomeric complexes with pathway-restricted Smad
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Figure 2 PT-PCR amplification of ActRs (Ia (A), IIa (B) and IIb (C)).
Ethidium bromide stained PCR-product for 28 cycles were separated on 1%
agarose gel. Lanes: 1, human cultured luteal-granulosa cells obtained from
IVF-ET patients; 2, OSE; 3, OVCAR 3; 4, SKOV 3. The PCR products were
transferred to nylon membrances and subjected to Southern hybridization
with ActRs (Ia (A), IIa (B) and IIb (C)) cDNA, and particularly ActR IIb was
shown below the ethidium bromide-stained gel
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Figure 3 Western blot analysis using ActR IIa and IIb antibodies on
cultured cells. Protein was extracted from samples lysed by lysis buffer.
Twenty-five micrograms protein per each lane were separated by SDS-PAGE
in the presence of 1% b-ME, using 8% gels. ActR IIa (A) and IIb (B) were
detected with polyclonal antibodies produced in rabbits by synthetic peptide
from the carboxy 1-terminal sequences of ActR IIa and IIb. Bound antibodies
were detected using an ECL detection kit. Lanes: 1, human cultured luteal-
granulosa cells obtained from IVF-ET patients; 2, OSE; 3, OVCAR 3; 4,
SKOV 3
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Aproteins, which translocate into the nucleus and activate transcrip-
tional responses. Activins act primarily through Smad 2, possibly
in partnership with Smad 4, which forms heteromeric complexes
with different ligand-specific Smads after activation. The principal
DNA-binding component of the activin-responsive factor (ARF) is
FAST-1 (Chen et al, 1996), a transcription factor with a novel
winged-helix structure; previous reports indicate that Smad 4
stabilizes a ligand-stimulated Smad 2–FAST-1 complex as an
active DNA-binding factor. Our data showed that OVCAR 3
expressed mRNAs of Smad 4 and Smad 2 proteins. While activin
had no effect on the expression of Smad 4 in OVCAR 3, it
increased the expression of Smad 2. These data suggest that activin
may stimulate the production of the protein involving its own
signalling system in order to enhance its own effects in OVCAR 3:
an autocrine loop is clearly in operation. The enhancement of
Smad 2 mRNA probably contributes to activin signal transduction
in a ligand-dependent manner in OVCAR 3. A previous study
demonstrated the presence of Mad 2 protein and transcript in gran-
ulosa cells and showed that its expression is up-regulated by TGF-
b (Li et al, 1997). These data also suggest a possible feedback
mechanism that enhances its own action. The present data support
the presence of identical up-regulation mechanisms in the action of
activin in the ovarian carcinoma cell line. These results permit a
better understanding of the first step in the mechanism of action of
the activin receptor and provide a good model for the interactions
occurring in activation or inhibition of activin responses.
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